Stay updated on IBI310 Combo vs Sorafenib in HCC Clinical Trial
Sign up to get notified when there's something new on the IBI310 Combo vs Sorafenib in HCC Clinical Trial page.

Latest updates to the IBI310 Combo vs Sorafenib in HCC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page's revision tag moved from v3.5.3 to v3.5.4, indicating a new version of the record history. This reflects an update to the page's metadata rather than changes to the underlying study data.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe Record History shows the latest revision updated to v3.5.3, replacing the previous v3.5.2. This indicates a new version of the study record has been published.SummaryDifference0.1%

- Check44 days agoChange DetectedRevision: v3.5.2 was added to the record history, and revision v3.5.0 was removed.SummaryDifference0.1%

- Check66 days agoChange DetectedRevision v3.5.0 adds Study Status, Contacts/Locations, and Study Design and marks the study as Completed; the prior update removed the Recruiting status and sponsor Innovent Biologics (Suzhou) Co. Ltd.SummaryDifference2%

- Check80 days agoChange DetectedThe record history now includes revision v3.4.3 and removes v3.4.2 from the history.SummaryDifference0.1%

- Check109 days agoChange DetectedThe history page adds Revision: v3.4.2 and removes the government funding notice and Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

Stay in the know with updates to IBI310 Combo vs Sorafenib in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IBI310 Combo vs Sorafenib in HCC Clinical Trial page.